Carlo Maria Rossi, Ingrid Terreehorst, Evaggelia Apostolidou, Martina Votto, Arzu Bakirtas, Antonella Cianferroni, George N. Konstantinou, Katerina Pantavou, Dario Antolin‐Amerigo, Enrico Heffler, Alberto Alvarez‐Perea, Montserrat Fernandez‐Rivas, Georgios K. Nikolopoulos, Oliver Pfaar, Constantinos Pitsios
The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or airborne allergens, following the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) 2020 guidelines. The literature search was performed in three databases (PubMed, Embase and Scopus). Databases were searched from inception to March 31st, 2023. A total of 17 studies met the criteria for inclusion in the review. Fifteen studies, comprising 3,302 patients, were on food desensitization, and the overall estimate of EoE incidence, combining the results of these individual studies, was 2.31% (95% CI 1.45, 3.36). Registered data reported de novo cases of eosinophilic esophagitis, and its diagnosis was usually made during the maintenance phase of food desensitization. With the adopted searching strategy, only two studies on sublingual immunotherapy with aeroallergens meeting the inclusion criteria were retrieved, comprising 1,436 patients and not reporting cases of EoE. The meta‐analysis showed that the development of EoE is a common adverse effect of oral immunotherapy with food allergens, whereas it is uncommon during sublingual immunotherapy with aeroallergens. Trial Registration: PROSPERO: CRD42023425917
欧洲过敏和临床免疫学学会（EAACI）成立了一个工作组来评估嗜酸性粒细胞性食管炎（EoE）和过敏原免疫治疗（AIT）之间关系的现有数据。本系统评价和荟萃分析旨在根据系统评价和荟萃分析（PRISMA） 2020指南的首选报告项目，研究确诊的EoE的发生率，这是AIT对食物或空气中过敏原的副作用。文献检索在PubMed、Embase和Scopus三个数据库中进行。数据库从成立到2023年3月31日进行了搜索。共有17项研究符合纳入本综述的标准。15项研究，包括3302名患者，是关于食物脱敏的，综合这些单独研究的结果，EoE发生率的总体估计为2.31% （95% CI 1.45, 3.36）。已登记的资料报道了嗜酸性粒细胞性食管炎的新发病例，其诊断通常在食物脱敏的维持阶段进行。采用检索策略，仅检索到两篇符合纳入标准的含气敏原的舌下免疫治疗研究，共1436例患者，未报告EoE病例。荟萃分析显示，EoE的发生是食物过敏原口服免疫治疗的常见不良反应，而在含空气过敏原的舌下免疫治疗中并不常见。试验注册：PROSPERO: CRD42023425917
{"title":"A Systematic Review and Meta‐Analysis on the Induction of Confirmed Eosinophilic Esophagitis as a Side Effect of Allergen Immunotherapy: An EAACI Task Force Report","authors":"Carlo Maria Rossi, Ingrid Terreehorst, Evaggelia Apostolidou, Martina Votto, Arzu Bakirtas, Antonella Cianferroni, George N. Konstantinou, Katerina Pantavou, Dario Antolin‐Amerigo, Enrico Heffler, Alberto Alvarez‐Perea, Montserrat Fernandez‐Rivas, Georgios K. Nikolopoulos, Oliver Pfaar, Constantinos Pitsios","doi":"10.1111/all.70183","DOIUrl":"https://doi.org/10.1111/all.70183","url":null,"abstract":"The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or airborne allergens, following the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) 2020 guidelines. The literature search was performed in three databases (PubMed, Embase and Scopus). Databases were searched from inception to March 31st, 2023. A total of 17 studies met the criteria for inclusion in the review. Fifteen studies, comprising 3,302 patients, were on food desensitization, and the overall estimate of EoE incidence, combining the results of these individual studies, was 2.31% (95% CI 1.45, 3.36). Registered data reported <jats:italic>de novo</jats:italic> cases of eosinophilic esophagitis, and its diagnosis was usually made during the maintenance phase of food desensitization. With the adopted searching strategy, only two studies on sublingual immunotherapy with aeroallergens meeting the inclusion criteria were retrieved, comprising 1,436 patients and not reporting cases of EoE. The meta‐analysis showed that the development of EoE is a common adverse effect of oral immunotherapy with food allergens, whereas it is uncommon during sublingual immunotherapy with aeroallergens. Trial Registration: PROSPERO: CRD42023425917","PeriodicalId":122,"journal":{"name":"Allergy","volume":"15 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145765226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emilia Vassilopoulou, Sophia Tsabouri, Stefania Arasi, Anna Comotti, Gregorio Paolo Milani, Klaudia Ryczaj, Carlo Agostoni, Ioannis Pagkalos, Berber Vlieg‐Boerstra, Chrystopherson Gengyny Caballero‐Lopez, Gavriela Feketea, Anna Nowak‐Wegrzyn, Susanne Halken, Burcin Beken, Montserrat Alvaro‐Lozano, Ines Padua, Mattia Giovannini, George Du Toit, Alberto Alvarez‐Perea, Roberto Berni Canani, Diego Peroni, Marina Pérez‐Gordo, Mohamed H. Shamji, Ludger Klimek, Ioana Agache, Elena Camelia Berghea, Franziska Roth‐Walter, Cevdet Ozdemir, Peter Smith, Liam O’ Mahony, Rosan W. Meyer, Carina Venter
Complementary feeding (CF) influences infants' long‐term dietary preferences, growth, and food allergy (FA) risk. However, guidance given to families and the implementation of FA prevention guidelines by healthcare professionals (HCPs) remain unclear. This study explored HCPs' perspectives and practices regarding CF strategies in the context of FA prevention across different regions and professional backgrounds. An online survey conducted by an EAACI task force between December 2023 and May 2024 assessed CF timing, allergenic food introduction, nutrient supplementation, and FA preventive measures. 550 HCPs (pediatricians, allergists, dietitians), 68% from Europe, participated. HCPs recommended CF initiation at a median of six months for breastfed infants and five months for formula‐fed and FA high‐risk infants. Atopic dermatitis (94%) and family history of allergies (87%) were the most recognized FA risk factors. Vitamin D (49%), probiotics (28%), and omega‐3 fatty acids (18%) were commonly recommended supplements. Regional, professional, and educational influences differences emerged, with Northern European HCPs favoring earlier CF and allergen introduction, often without structured guidance. Southern European HCPs preferred a structured sequence and later CF initiation. A flexible, evidence‐based framework is needed to guide FA prevention while accommodating cultural and geographical differences.
{"title":"Healthcare Professional Survey on Complementary Feeding and Allergy Prevention in High‐ Versus Low‐Risk Infants: An EAACI Task Force Report","authors":"Emilia Vassilopoulou, Sophia Tsabouri, Stefania Arasi, Anna Comotti, Gregorio Paolo Milani, Klaudia Ryczaj, Carlo Agostoni, Ioannis Pagkalos, Berber Vlieg‐Boerstra, Chrystopherson Gengyny Caballero‐Lopez, Gavriela Feketea, Anna Nowak‐Wegrzyn, Susanne Halken, Burcin Beken, Montserrat Alvaro‐Lozano, Ines Padua, Mattia Giovannini, George Du Toit, Alberto Alvarez‐Perea, Roberto Berni Canani, Diego Peroni, Marina Pérez‐Gordo, Mohamed H. Shamji, Ludger Klimek, Ioana Agache, Elena Camelia Berghea, Franziska Roth‐Walter, Cevdet Ozdemir, Peter Smith, Liam O’ Mahony, Rosan W. Meyer, Carina Venter","doi":"10.1111/all.70188","DOIUrl":"https://doi.org/10.1111/all.70188","url":null,"abstract":"Complementary feeding (CF) influences infants' long‐term dietary preferences, growth, and food allergy (FA) risk. However, guidance given to families and the implementation of FA prevention guidelines by healthcare professionals (HCPs) remain unclear. This study explored HCPs' perspectives and practices regarding CF strategies in the context of FA prevention across different regions and professional backgrounds. An online survey conducted by an EAACI task force between December 2023 and May 2024 assessed CF timing, allergenic food introduction, nutrient supplementation, and FA preventive measures. 550 HCPs (pediatricians, allergists, dietitians), 68% from Europe, participated. HCPs recommended CF initiation at a median of six months for breastfed infants and five months for formula‐fed and FA high‐risk infants. Atopic dermatitis (94%) and family history of allergies (87%) were the most recognized FA risk factors. Vitamin D (49%), probiotics (28%), and omega‐3 fatty acids (18%) were commonly recommended supplements. Regional, professional, and educational influences differences emerged, with Northern European HCPs favoring earlier CF and allergen introduction, often without structured guidance. Southern European HCPs preferred a structured sequence and later CF initiation. A flexible, evidence‐based framework is needed to guide FA prevention while accommodating cultural and geographical differences.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"29 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145730993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tari Haahtela, Liam O'Mahony, Claudia Traidl‐Hoffmann, Mubeccel Akdis, Ozlem Ceylan, Panagiotis Chaslaridis, Athanasios Damialis, Stefano Del Giacco, Antti Lauerma, Kari C. Nadeau, Inês Paciência, Isabella Pali‐Schöll, Oscar Palomares, Harald Renz, Jurgen Schwarze, Marilyn Urrutia‐Pereira, Carina Venter, Donata Vercelli, Tonya Winders, Cezmi A. Akdis, Marek Jutel, Ioana Agache
The allergy and asthma epidemic in urban societies following World War II is mostly caused by changes in the environment, diet and lifestyle. Disconnection of urban populations from the wider environment has reduced the protective factors building up immunological resilience. The European Academy of Allergy and Clinical Immunology (EAACI) guidelines on greenness impact on allergy and asthma follow the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach and provide eight recommendations encouraging greenness exposure to support immune health. Controlled follow‐up studies are still scarce, and the strength of evidence is generally low or moderate at best. For primary prevention of allergy and asthma, most of the evidence indicates beneficial effects. Exposure is also useful for secondary prevention. Asthma patients may feel better and need less medication by combining green space exposure with physical activity. During the high‐pollen season, effective seasonal medication is necessary for patients with pollen allergy. In urban planning, implementing appropriate green infrastructure and easy access to green space promotes immune health and reduces risks of air pollution and heatwaves. These EAACI guidelines are the first recommendations highlighting the importance of urban green spaces on immune health and call for prioritising innovative research in this field.
{"title":"EAACI Guidelines on the Importance of Green Space in Urban Environments for Allergy and Asthma Prevention","authors":"Tari Haahtela, Liam O'Mahony, Claudia Traidl‐Hoffmann, Mubeccel Akdis, Ozlem Ceylan, Panagiotis Chaslaridis, Athanasios Damialis, Stefano Del Giacco, Antti Lauerma, Kari C. Nadeau, Inês Paciência, Isabella Pali‐Schöll, Oscar Palomares, Harald Renz, Jurgen Schwarze, Marilyn Urrutia‐Pereira, Carina Venter, Donata Vercelli, Tonya Winders, Cezmi A. Akdis, Marek Jutel, Ioana Agache","doi":"10.1111/all.70182","DOIUrl":"https://doi.org/10.1111/all.70182","url":null,"abstract":"The allergy and asthma epidemic in urban societies following World War II is mostly caused by changes in the environment, diet and lifestyle. Disconnection of urban populations from the wider environment has reduced the protective factors building up immunological resilience. The European Academy of Allergy and Clinical Immunology (EAACI) guidelines on greenness impact on allergy and asthma follow the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach and provide eight recommendations encouraging greenness exposure to support immune health. Controlled follow‐up studies are still scarce, and the strength of evidence is generally low or moderate at best. For primary prevention of allergy and asthma, most of the evidence indicates beneficial effects. Exposure is also useful for secondary prevention. Asthma patients may feel better and need less medication by combining green space exposure with physical activity. During the high‐pollen season, effective seasonal medication is necessary for patients with pollen allergy. In urban planning, implementing appropriate green infrastructure and easy access to green space promotes immune health and reduces risks of air pollution and heatwaves. These EAACI guidelines are the first recommendations highlighting the importance of urban green spaces on immune health and call for prioritising innovative research in this field.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"6 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nami Shrestha Palikhe, Yingqi Wu, Karen J. Howie, Caitlin Stevens, Jennifer Mitchell, Lesley Wiltshire, Gail M. Gauvreau, Harissios Vliagoftis
{"title":"Monocyte Chemotactic Factors in the Airways of Patients With Mild Asthma Before and After an Allergen Challenge","authors":"Nami Shrestha Palikhe, Yingqi Wu, Karen J. Howie, Caitlin Stevens, Jennifer Mitchell, Lesley Wiltshire, Gail M. Gauvreau, Harissios Vliagoftis","doi":"10.1111/all.70192","DOIUrl":"https://doi.org/10.1111/all.70192","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"143 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145730992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comprehensive Analysis of Food Allergy Research Trends via Large Language Model-Assisted Text Mining (1980-2024).","authors":"Yoshiyuki Kobayashi,Takahiro Inoue,Itsuki Kageyama,Yusuke Iwasaki,Rie Ito,Kota Kodama,Hiroshi Akiyama","doi":"10.1111/all.70169","DOIUrl":"https://doi.org/10.1111/all.70169","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"8 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145710868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lian F. van der Gang, Celeste M. Boesjes, Nicolaas P. A. Zuithoff, Inge Haeck, Octavian Bacoş‐Cosma, Laura Loman, Keneshka Atash, Veroniek Harbers, Simone Stadhouders, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Klaziena Politiek, Antoni Gostynski, Wianda A. Christoffers, Floor M. Garritsen, Annebeth Flinterman, Wouter R. H. Touwslager, Berit Velstra, Shiarra M. Stewart, Francine C. van Erp, Annemie F. S. Galimont‐Collen, Marie‐Louise A. Schuttelaar, Marlies de Graaf, Marjolein S. de Bruin‐Weller
{"title":"Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry","authors":"Lian F. van der Gang, Celeste M. Boesjes, Nicolaas P. A. Zuithoff, Inge Haeck, Octavian Bacoş‐Cosma, Laura Loman, Keneshka Atash, Veroniek Harbers, Simone Stadhouders, Albert J. Oosting, Anneke M. T. van Lynden‐van Nes, Klaziena Politiek, Antoni Gostynski, Wianda A. Christoffers, Floor M. Garritsen, Annebeth Flinterman, Wouter R. H. Touwslager, Berit Velstra, Shiarra M. Stewart, Francine C. van Erp, Annemie F. S. Galimont‐Collen, Marie‐Louise A. Schuttelaar, Marlies de Graaf, Marjolein S. de Bruin‐Weller","doi":"10.1111/all.70187","DOIUrl":"https://doi.org/10.1111/all.70187","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"29 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145704143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joana Antão,Guilherme Rodrigues,Nazanin Zounemat-Kermani,Paolo Montuschi,Qichen Deng,Frits M E Franssen,Lars I Andersson,Ian M Adcock,Sven-Erik Dahlén,Scott S Wagers,Martijn A Spruit,Alda Marques,
BACKGROUNDControlling asthma symptoms remains challenging. Understanding its molecular mechanisms may provide new insights into asthma pathophysiology. We explored the associations between the transcriptome and proteome in blood and sputum and asthma symptom control.METHODSThis cross-sectional study included asthmatic and healthy adults from the U-BIOPRED cohort. Uncontrolled symptoms were defined as a mean ≥ 1.5 points on the 5-item asthma control questionnaire. Stability selection using LASSO logistic regression identified genes/proteins associated with symptom control, followed by logistic regression. Analyses were adjusted for age, sex, age of asthma onset, smoking status, body mass index (BMI), FEV1% predicted, exacerbation history, anti-IgE therapy and urinary steroid levels. The selected variables were compared with healthy controls using linear regression, adjusted for age, sex, BMI, smoking status and urinary steroid levels.RESULTSFour serum proteins were selected based on data from 415 asthmatics (median age 52 [41, 61] years; 59% female; 64% uncontrolled). Higher TWEAKR/TNFRSF12A [OR 2.25 (95% CI 1.15, 4.77)] and MBL/MBP-C [1.6 (1.07, 2.42)] levels increased the odds of uncontrolled symptoms, whereas higher MK08/MAPK8 [0.48 (0.29, 0.76)] and CD5L [0.59 (0.41, 0.82)] levels decreased the odds. CD5L levels were significantly lower in severe asthma than in healthy controls [estimate -0.23 (95% CI -0.41, -0.04)]. No associations were found between symptom control and the sputum proteome (N = 90) or the sputum (N = 96) and blood (N = 360) transcriptomes.CONCLUSIONFour serum proteins distinguished asthmatics with uncontrolled from controlled symptoms. CD5L levels were also lower in asthmatics with severe disease than in healthy controls, warranting further investigation into its potential therapeutic value.
背景：控制哮喘症状仍然具有挑战性。了解其分子机制可能为哮喘病理生理学提供新的见解。我们探讨了血液和痰中转录组和蛋白质组与哮喘症状控制之间的关系。方法本横断面研究包括来自U-BIOPRED队列的哮喘和健康成人。未控制症状定义为在5项哮喘控制问卷中平均≥1.5分。使用LASSO逻辑回归进行稳定性选择，确定与症状控制相关的基因/蛋白质，然后进行逻辑回归。分析调整了年龄、性别、哮喘发病年龄、吸烟状况、体重指数（BMI）、预测FEV1%、加重史、抗ige治疗和尿类固醇水平。选择的变量与健康对照使用线性回归进行比较，调整年龄、性别、BMI、吸烟状况和尿类固醇水平。结果从415例哮喘患者（中位年龄52岁[41,61]，女性59%，未控制者64%）中选择4种血清蛋白。较高的TWEAKR/TNFRSF12A [OR 2.25 (95% CI 1.15, 4.77)]和MBL/MBP-C[1.6(1.07, 2.42))]水平增加了症状失控的几率，而较高的MK08/MAPK8[0.48(0.29, 0.76)]和CD5L[0.59(0.41, 0.82)]水平降低了症状失控的几率。严重哮喘患者的CD5L水平显著低于健康对照组[估计值-0.23 (95% CI -0.41, -0.04)]。症状控制与痰蛋白组（N = 90）或痰转录组（N = 96）和血转录组（N = 360）之间没有关联。结论4种血清蛋白可区分哮喘控制症状与控制症状。患有严重疾病的哮喘患者的CD5L水平也低于健康对照组，值得进一步研究其潜在的治疗价值。
{"title":"Proteomic and Transcriptomic Signatures of Poor Asthma Symptom Control in the U-BIOPRED Cohort.","authors":"Joana Antão,Guilherme Rodrigues,Nazanin Zounemat-Kermani,Paolo Montuschi,Qichen Deng,Frits M E Franssen,Lars I Andersson,Ian M Adcock,Sven-Erik Dahlén,Scott S Wagers,Martijn A Spruit,Alda Marques, ","doi":"10.1111/all.70178","DOIUrl":"https://doi.org/10.1111/all.70178","url":null,"abstract":"BACKGROUNDControlling asthma symptoms remains challenging. Understanding its molecular mechanisms may provide new insights into asthma pathophysiology. We explored the associations between the transcriptome and proteome in blood and sputum and asthma symptom control.METHODSThis cross-sectional study included asthmatic and healthy adults from the U-BIOPRED cohort. Uncontrolled symptoms were defined as a mean ≥ 1.5 points on the 5-item asthma control questionnaire. Stability selection using LASSO logistic regression identified genes/proteins associated with symptom control, followed by logistic regression. Analyses were adjusted for age, sex, age of asthma onset, smoking status, body mass index (BMI), FEV1% predicted, exacerbation history, anti-IgE therapy and urinary steroid levels. The selected variables were compared with healthy controls using linear regression, adjusted for age, sex, BMI, smoking status and urinary steroid levels.RESULTSFour serum proteins were selected based on data from 415 asthmatics (median age 52 [41, 61] years; 59% female; 64% uncontrolled). Higher TWEAKR/TNFRSF12A [OR 2.25 (95% CI 1.15, 4.77)] and MBL/MBP-C [1.6 (1.07, 2.42)] levels increased the odds of uncontrolled symptoms, whereas higher MK08/MAPK8 [0.48 (0.29, 0.76)] and CD5L [0.59 (0.41, 0.82)] levels decreased the odds. CD5L levels were significantly lower in severe asthma than in healthy controls [estimate -0.23 (95% CI -0.41, -0.04)]. No associations were found between symptom control and the sputum proteome (N = 90) or the sputum (N = 96) and blood (N = 360) transcriptomes.CONCLUSIONFour serum proteins distinguished asthmatics with uncontrolled from controlled symptoms. CD5L levels were also lower in asthmatics with severe disease than in healthy controls, warranting further investigation into its potential therapeutic value.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"135 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana M Gimenez-Arnau,Marcus Maurer,Adam Reich,Chia-Yu Chu,Diana Deleanu,Gordon Sussman,Jorge Sanchez,Knut Brockow,Koremasa Hayama,Michihiro Hide,Mohamed Denguezli,Raisa Meshkova,Roberta F J Criado,Sarbjit Saini,Solange Valle,Eva Hua,Pengpeng Wang,Alis Burciu,Isabelle Indermuehle,Vineeth Varanasi,Yolandi Joubert,Thomas Severin,Manmath Patekar
BACKGROUNDChronic spontaneous urticaria (CSU) is a debilitating skin condition affecting approximately 1% of the global population, characterized by recurrent wheals, angioedema, or both for over 6 weeks without identifiable external triggers.METHODSThis Phase 3b multicentre, double-blinded followed by open-label extension study evaluated the long-term efficacy and safety of ligelizumab re-treatment in patients with CSU who rolled over from previous studies. Patients from the PEARL-1 or PEARL-2 Phase 3 trials (re-treatment subpopulation) received blinded re-treatment with ligelizumab 72 mg or 120 mg every 4 weeks for 12 weeks, followed by open-label ligelizumab 120 mg up to Week 104. Patients from a Phase 3 open-label Japanese study or a Phase 2 pediatric study received open-label ligelizumab 120 mg throughout. Primary and key secondary efficacy endpoints were assessed at Week 12 in the re-treatment subpopulation; safety was evaluated throughout.RESULTSIn the overall ligelizumab re-treatment subpopulation, 53.5% and 57.5% of patients treated with ligelizumab 72 mg and 120 mg, respectively, achieved weekly urticaria activity score (UAS7) of ≤ 6 at Week 12. Re-treatment efficacy was demonstrated in both treatment arms, across all secondary endpoints, maintained up to Week 52. Re-treatment efficacy in the overall trial population showed similar trends to those in the re-treatment subpopulation. The safety profile of ligelizumab showed no new or unexpected safety signals compared with the known safety profile of ligelizumab.CONCLUSIONLong-term and re-treatment with ligelizumab was well tolerated and efficacious in patients with CSU, aligning with the short-term outcomes observed in the Phase 3 PEARL studies.
{"title":"Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.","authors":"Ana M Gimenez-Arnau,Marcus Maurer,Adam Reich,Chia-Yu Chu,Diana Deleanu,Gordon Sussman,Jorge Sanchez,Knut Brockow,Koremasa Hayama,Michihiro Hide,Mohamed Denguezli,Raisa Meshkova,Roberta F J Criado,Sarbjit Saini,Solange Valle,Eva Hua,Pengpeng Wang,Alis Burciu,Isabelle Indermuehle,Vineeth Varanasi,Yolandi Joubert,Thomas Severin,Manmath Patekar","doi":"10.1111/all.70181","DOIUrl":"https://doi.org/10.1111/all.70181","url":null,"abstract":"BACKGROUNDChronic spontaneous urticaria (CSU) is a debilitating skin condition affecting approximately 1% of the global population, characterized by recurrent wheals, angioedema, or both for over 6 weeks without identifiable external triggers.METHODSThis Phase 3b multicentre, double-blinded followed by open-label extension study evaluated the long-term efficacy and safety of ligelizumab re-treatment in patients with CSU who rolled over from previous studies. Patients from the PEARL-1 or PEARL-2 Phase 3 trials (re-treatment subpopulation) received blinded re-treatment with ligelizumab 72 mg or 120 mg every 4 weeks for 12 weeks, followed by open-label ligelizumab 120 mg up to Week 104. Patients from a Phase 3 open-label Japanese study or a Phase 2 pediatric study received open-label ligelizumab 120 mg throughout. Primary and key secondary efficacy endpoints were assessed at Week 12 in the re-treatment subpopulation; safety was evaluated throughout.RESULTSIn the overall ligelizumab re-treatment subpopulation, 53.5% and 57.5% of patients treated with ligelizumab 72 mg and 120 mg, respectively, achieved weekly urticaria activity score (UAS7) of ≤ 6 at Week 12. Re-treatment efficacy was demonstrated in both treatment arms, across all secondary endpoints, maintained up to Week 52. Re-treatment efficacy in the overall trial population showed similar trends to those in the re-treatment subpopulation. The safety profile of ligelizumab showed no new or unexpected safety signals compared with the known safety profile of ligelizumab.CONCLUSIONLong-term and re-treatment with ligelizumab was well tolerated and efficacious in patients with CSU, aligning with the short-term outcomes observed in the Phase 3 PEARL studies.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"242 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian
{"title":"Unveiling Rare Genetic Variants in DAB2IP : New Insights Into the Pathogenesis of Recurrent Angioedema","authors":"Maurizio Margaglione, Maria D'Apolito, Rosa Santacroce, Giorgia Cordisco, Francesco Arcoleo, Tiziana De Pasquale, Ilaria Puxeddu, Andrea Zanichelli, Mauro Cancian","doi":"10.1111/all.70184","DOIUrl":"https://doi.org/10.1111/all.70184","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"20 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145680342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：